Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16

Phase 1

• Conditions: Anogenital (venereal) warts; A63.0; Genital Wart.

• Registration Number: IRCT20190504043464N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

1- People Voluntarily Participate in the Research.
2- The Informed Consent Form Is Completed and Signed by the Person or Her companion.
3- Women PCR positive test for Papilloma Virus Infection.
4. Women Don't Have other sexually transmitted diseases.
Women Don't be Pregnant
6. Women in Pap smear Test Don't Have Abnormal Conditions.

Exclusion Criteria

1. People Don't Have Cancerous Disease During the Course of Treatment.
2. Failure to Complete a Course of Treatment by Individuals Will Result in Their Exclusion from Study.
3- Getting Pregnant During the Course of Treatment Will Leave Women Out of Study.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Antibody and Interferon Levels. Timepoint: At the Beginning of the Study, 30, 60 and 90 Days After Taking the Vaccine. Method of measurement: ELISA And ELISPOT KITS.